The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Effect of cytarabine/anthracycline/crenolanib induction on minimal residual disease (MRD) in newly diagnosed FLT3 mutant AML.
 
Richard M. Stone
Consulting or Advisory Role - Abbvie; Agios; Amgen; Bristol-Myers Squibb; Celator; Celgene; Fujifilm; Juno Therapeutics; Karyopharm Therapeutics; Merck; Novartis; Ono Pharmaceutical; Roche/Genentech; Theradex
Research Funding - Agios (Inst); Celator (Inst); Karyopharm Therapeutics (Inst); Novartis (Inst)
 
Robert Collins
Honoraria - Optum
Travel, Accommodations, Expenses - Optum
 
Martin S. Tallman
No Relationships to Disclose
 
Roland B. Walter
Consulting or Advisory Role - Agios; Amphivena Therapeutics, Inc.; AstraZeneca; BiolineRx; Celgene; Covagen AG; Emergent BioSolutions; Janssen Research & Development; Pfizer; Seagen
Research Funding - Abbvie; ADC Therapeutics; Amgen; Amgen; Amphivena Therapeutics, Inc.; Arog; Celator; Covagen AG; CSL Behring; Pharmacyclics; Seagen; Seagen; Stemline Therapeutics
Patents, Royalties, Other Intellectual Property - First Named Inventor: Combination of epigenetic factors and bispecific compounds targeting CD33 and CD3 in the treatment of myeloid leukemia. U.S. Patent and Trademark Office, application number 61877714; filed September 13, 2013.
 
Chatchada Karanes
No Relationships to Disclose
 
Prapti Arvind Patel
No Relationships to Disclose
 
Madhuri Vusirikala
Consulting or Advisory Role - Amgen
 
Catherine Callaghan Coombs
Consulting or Advisory Role - H3 Biomedicine
 
Gretchen Olson
No Relationships to Disclose
 
Vinay Kumar Jain
Employment - Arog
Leadership - Arog
Stock and Other Ownership Interests - Arog
 
Eunice S. Wang
Consulting or Advisory Role - Amgen; Daiichi Sankyo; Seagen; Sigma-Tau; Spectrum Pharmaceuticals
Speakers' Bureau - Incyte
Research Funding - Immunogen (Inst)